Revolutionary Blood Pressure Monitor, ViCardio®, is “upbeat” after being named as Innovator of the year 2018 at the Future Health Summit Conference in Dublin

Revolutionary Blood Pressure Monitor, ViCardio®, is “upbeat” after being named as Innovator of the year 2018 at the Future Health Summit Conference in Dublin

ViCardio® is delighted to announce that it was awarded Innovator of the Year  at the Future Health Summit 2018 in Dublin on Tuesday 29th May for its revolutionary, beat to beat, wearable blood pressure monitor.

 

The Future Health Summit is a global gathering for Healthcare, held in Ireland. It is made up of 14 conferences with over 1500 delegates. This year’s conference focused on healthcare systems and empowering the patient with an emphasis on digital health and wearables.

 

Receiving the award for ViCardio®, Dr David Pearce, highlighted the inadequacies of both current cuff based devices and the lack of any other, credible, emerging technologies. He emphasised the importance of accuracy and the discipline of regulatory compliance that is so crucial if sensor technology is going to be of credible benefit to patients and clinicians.

 

Pearce said: “There is a huge potential for ViCardio and other emerging wearable technology to make a positive impact on the diagnosis and treatment of major global health problems, but there is also a significant danger that unregulated, and partially accurate consumer electronics devices will lead to the rapid disengagement by patients and their healthcare providers. 

With reducing margins between normal and treatable blood pressure, the increased accuracy and frequency of measurement is key. That is what ViCardio aims to deliver.”

 

The ViCardio® TLT sensor is completing a rigorous clinical trial at the world famous Barts Heart Centre in London, where it is being compared to intra-arterial monitoring lines. Following that CE Mark and FDA Clearance will be sought. The company is confident that it is on track to deliver a performance medical grade device to consumers and clinicians in Q4 2018.

Comments are closed.